Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q1 2025 · 10-Q
Revenue—
Net Income-$8.19M-$8.19MN/M vs Q1 2024 EPS Diluted-$0.74-$0.74N/M vs Q1 2024 Operating Income-$7,871,000N/M Operating Cash Flow-$6,768,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end